SKSusanne M. Kooistra

Susanne M. Kooistra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Susanne M. Kooistra has a total of 117 co-authors. Here are the top co-authors by number of shared publications:

  • Bart J. L. Eggen

    Department of Biomedical Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

    18 shared publications
  • Nieske Brouwer

    Department of Biomedical Sciences University of Groningen, University Medical Center Groningen Groningen the Netherlands

    10 shared publications
  • Evelyn M. Wesseling

    University Medical Center Groningen

    7 shared publications
  • Anneke Miedema

    Department of Biomedical Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

    6 shared publications
  • Bart J.L. Eggen

    University Medical Center Groningen

    4 shared publications
  • Marissa L. Dubbelaar

    Department of Biomedical Sciences of Cells & Systems, Section Molecular Neurobiology University of Groningen, University Medical Center Groningen Groningen The Netherlands

    4 shared publications

Latest Publications

  • Open Access

    Predicting Relevant Microglia‐Associated Cell–Cell Communication Pathways in Alzheimer's Disease: A Role for SPP1

    by Janssen M. Kotah, Marina Trombetta Lima, Esmée C. Dragt, Asimenia Voulgaroglou, Nieske Brouwer, Inge R. Holtman, Susanne M. Kooistra, Bart J. L. Eggen

    Microglia play a key role in the pathophysiology of Alzheimer's Disease (AD) and their increased heterogeneity likely affects disease progression. We previously identified distinct microglial signatures that were enriched in AD donors and associated with amyloid and tau, respectively. Here we generated a snRNAseq dataset from postmortem control and AD cases and analyzed alterations in cell–cell communication pathways that might be relevant to AD pathophysiology. One signaling pathway perturbed in AD cases involved SPP1 , and while this pathway was also present in control samples, microglia–microglia SPP1 signaling was restricted to AD donors. Further analyses within microglia–microglia signaling predict AD‐specific induction of GAS6‐AXL signaling (from inflammatory and ribosomal microglia), and SPP1‐ITGAV/ITGB5 signaling (from disease‐associated and inflammatory microglia, among others). Together, these findings might in part explain the increased microglia phagocytic profile described in AD. RNAscope confirmed enrichment of SPP1 expressing microglia near amyloid plaques in AD brain tissue samples. These data indicate altered cellular communications between microglia in the AD brain.


  • Top Cited Papers

    Microglial states revisited: from homeostasis to disease

    by Bart J. L. Eggen, Susanne M. Kooistra


  • Open Access

    Beyond the nuclear border: single-cell analysis of in situ sequenced human brain tissue using cellular features

    by Janssen M. Kotah, Thomas Rust, Hilmar R. J. van Weering, Janneke Bosma, Amber L. Woudstra, Susanne M. Kooistra, Bart J. L. Eggen

    Spatial transcriptomics has advanced our understanding of cellular heterogeneity at single-cell resolution. Here, we assess the suitability of in situ sequencing (ISS) for analyzing formalin-fixed, paraffin-embedded (FFPE) postmortem human brain tissue. A key challenge in ISS data analysis is optimizing transcript allocation while minimizing misallocation, particularly in the morphologically complex central nervous system (CNS). We compared geospatial methods using nuclear and expanded nuclear boundaries for segmentation and transcript allocation. While overall cell-type proportions remained comparable, transcript allocation methods affected specific cell types, including microglia, neurons, and neurovascular cells. To enhance specificity, we integrated fluorescent imaging data targeting 18S RNA and IBA1 protein to direct transcript allocation toward RNA-rich cells (e.g., neurons) and microglia, respectively. We demonstrate how this approach, paired with secondary allocation of transcripts outside imaging masks, improved both the number of microglia detected and the specificity of microglial transcripts assigned. Our method offers a flexible and efficient strategy for targeted transcript allocation based on cellular morphology, optimizing CNS cell segmentation in FFPE-preserved human brain tissue.


  • Open Access

    Microglia endotoxin tolerance is retained after enforced repopulation

    by Tiago Medeiros-Furquim, Anneke Miedema, Edwin Schilder, Nieske Brouwer, Inge R. Holtman, Susanne M. Kooistra, Bart J.L. Eggen


  • Open Access

    Multiple Sclerosis: Glial Cell Diversity in Time and Space

    by Susanne M. Kooistra, Lucas Schirmer

    Multiple sclerosis (MS) is the most prevalent human inflammatory disease of the central nervous system with demyelination and glial scar formation as pathological hallmarks. Glial cells are key drivers of lesion progression in MS with roles in both tissue damage and repair depending on the surrounding microenvironment and the functional state of the individual glial subtype. In this review, we describe recent developments in the context of glial cell diversity in MS summarizing key findings with respect to pathological and maladaptive functions related to disease‐associated glial subtypes. A particular focus is on the spatial and temporal dynamics of glial cells including subtypes of microglia, oligodendrocytes, and astrocytes. We contextualize recent high‐dimensional findings suggesting that glial cells dynamically change with respect to epigenomic, transcriptomic, and metabolic features across the inflamed rim and during the progression of MS lesions. In summary, detailed knowledge of spatially restricted glial subtype functions is critical for a better understanding of MS pathology and its pathogenesis as well as the development of novel MS therapies targeting specific glial cell types.


  • Spatially resolved gene signatures of white matter lesion progression in multiple sclerosis

    by Astrid M. Alsema, Marion H. C. Wijering, Anneke Miedema, Janssen M. Kotah, Mirjam Koster, Merel Rijnsburger, Hilmar R. J. van Weering, Helga E. de Vries, Wia Baron, Susanne M. Kooistra, et al.

    Multiple sclerosis (MS) is an inflammatory disease of the central nervous system characterized by myelin loss and progressive neurodegeneration. To understand MS lesion initiation and progression, we generate spatial gene expression maps of white matter (WM) and grey matter (GM) MS lesions. In different MS lesion types, we detect domains characterized by a distinct gene signature, including an identifiable rim around active WM lesions. Expression changes in astrocyte-specific, oligodendrocyte-specific and microglia-specific gene sets characterize the active lesion rims. Furthermore, we identify three WM lesion progression trajectories, predicting how normal-appearing WM can develop into WM active or mixed active–inactive lesions. Our data shed light on the dynamic progression of MS lesions.


  • Pathological ultrastructural alterations of myelinated axons in normal appearing white matter in progressive multiple sclerosis

    by Wendy Oost, Allard J. Huitema, Kim Kats, Ben N. G. Giepmans, Susanne M. Kooistra, Bart J. L. Eggen, Wia Baron

    BioStudies – one package for all the data supporting a study

  • Top Cited Papers
    Open Access

    The role of microglia in early neurodevelopment and the effects of maternal immune activation

    by L. J. M. Mastenbroek, S. M. Kooistra, B. J. L. Eggen, J. R. Prins

    Activation of the maternal immune system during gestation has been associated with an increased risk for neurodevelopmental disorders in the offspring, particularly schizophrenia and autism spectrum disorder. Microglia, the tissue-resident macrophages of the central nervous system, are implicated as potential mediators of this increased risk. Early in development, microglia start populating the embryonic central nervous system and in addition to their traditional role as immune responders under homeostatic conditions, microglia are also intricately involved in various early neurodevelopmental processes. The timing of immune activation may interfere with microglia functioning during early neurodevelopment, potentially leading to long-term consequences in postnatal life. In this review we will discuss the involvement of microglia in brain development during the prenatal and early postnatal stages of life, while also examining the effects of maternal immune activation on microglia and neurodevelopmental processes. Additionally, we discuss recent single cell RNA-sequencing studies focusing on microglia during prenatal development, and hypothesize how early life microglial priming, potentially through epigenetic reprogramming, may be related to neurodevelopmental disorders.


  • Open Access

    Identification of regional astrocyte heterogeneity associated with cuprizone-induced de- and remyelination using spatial transcriptomics

    by Anneke Miedema, Marion H.C. Wijering, Astrid M. Alsema, Emma Gerrits, Michel Meijer, Mirjam Koster, Evelyn M. Wesseling, Wia Baron, Bart J.L. Eggen, Susanne M. Kooistra

    The cuprizone model is a well-characterized model to study processes of demyelination and remyelination, which are known features of multiple sclerosis. Cuprizone induces oligodendrocyte loss and severe demyelination in the brain, including the corpus callosum, hippocampus, and cortex. Loss of oligodendrocytes and myelin is accompanied by microgliosis and astrogliosis, wherein microglia and astrocytes partially lose their homeostatic functions and acquire a reactive/activated state. Cuprizone-induced demyelination peaks later in grey matter (GM) than in white matter (WM), and remyelination is more efficient in WM areas. Here, we aim to better understand regional diversity in microglia, astrocytes, and oligodendrocytes and their respective role in remyelination efficiency, by characterizing their response to cuprizone across brain regions. We applied spatial transcriptomics (ST) for unbiased gene activity profiling of multiple brain regions in a single tissue section, to identify region-associated changes in gene activity following cuprizone treatment. Gene activity changes were detected in highly abundant cell types, like neurons, oligodendrocytes, and astrocytes, but challenging to detect in low-abundant cell types such as microglia and oligodendrocyte precursor cells. ST revealed a significant increase in the expression of astrocyte markers Clu , Slc1a3, and Gfap during the demyelination phase in the WM fiber tract. In the cortex, the changes in GFAP expression were less prominent, both at the transcriptional and protein level. By mapping genes obtained from scRNAseq of FACS-sorted ACSA2-positive astrocytes onto the ST data, we observed astrocyte heterogeneity beyond the simple classification of WM– and GM-astrocytes in both control and cuprizone-treated mice. In the future, the characterization of these regional astrocyte populations could aid the development of novel strategies to halt the progression of demyelination and support remyelination. Highlights: ⍰ Astrocyte markers Clu , Slc1a3, and Gfap are increased in WM fiber tracts during demyelination ⍰ Expression dynamics of astrogliosis markers Gfap and Vim during de-and remyelination depend on the brain region ⍰ Combining scRNAseq with ST data revealed astrocyte heterogeneity beyond WM– and GM-differences ⍰ scRNAseq-identified gene sets were differently affected by cuprizone treatment across brain regions


  • Open Access

    IRF5 regulates microglial myelin clearance and cholesterol metabolism after demyelination

    by Alejandro Montilla, Alazne Zabala, Ibai Calvo, Paloma Mata, Irene Tomé, Mirjam Koster, Amanda Sierra, Susanne M. Kooistra, Federico Nicolás Soria, Bart J.L. Eggen, et al.

    Interferon regulatory factor 5 (IRF5), a transcription factor highly involved in innate immunity that drives microglia/macrophage towards a pro-inflammatory state, has been associated to multiple sclerosis susceptibility but its role in MS pathogenesis is unknown. Here we analysed the role of IRF5 in multiple sclerosis animal models. Irf 5 -/- mice showed exacerbated damage in the chronic phase of experimental autoimmune encephalomyelitis (EAE) mice, despite an initial delay in its onset, as well as after lysolecithin injection into the spinal cord. Transcriptomic and lipidomic analysis evidence a role of this transcription factor in myelin metabolism and cholesterol homeostasis. Indeed, Irf 5 -/- mice showed an aberrant accumulation of myelin debris and lipidic structures, such as CE-containing lipid droplets and cholesterol crystals, suggesting that myelin-derived lipids are not properly processed. Cholesterol crystal accumulation leads to an aberrant inflammatory response, which block oligodendrocyte migration into the core of demyelinated lesion and remyelination. Pharmacologically facilitating cholesterol transport reduces lipid droplet accumulation and ameliorates EAE exacerbated damage in Irf 5 -/- mice. These results reveal for the first time the role of Irf5, a transcription factor necessary to orchestrate the immune responses, in phagocytes lipid metabolism which could be pivotal in regenerative responses such as remyelination.